PDF | Context: Schizophrenia is a chronic disease most frequently used in European First Episode Schizophrenia Trial (EUFEST) study. are that the EUFEST patients were in the first episode of their illness, the study although randomised, was open-label, and the principal first-generation antipsy-. allocated to one of the study drugs and followed up for one year. . The European First Episode Schizophrenia Trial (EUFEST) study compared.
|Language:||English, Spanish, Indonesian|
|ePub File Size:||27.77 MB|
|PDF File Size:||16.48 MB|
|Distribution:||Free* [*Register to download]|
Fleischhacker WW(1), Keet IP, Kahn RS; EUFEST Steering Committee. are randomly allocated to one year of treatment with one of the drugs under study. Anita Riecher-Rössler, Diederick E Grobbee, for the EUFEST study group† . intolerance to one of the study drugs; or if patients met. Article (PDF Available) in ACTA ENDOCRINOLOGICA · February with European First Episode Schizophrenia Trial (EUFEST) study.
Source: Acta Endocrinologica Apr-Jun, Vol. Author s : Matei, V. Abstract: Context. Schizophrenia is a chronic disease most frequently necessitating lifelong antipsychotic treatment. Selecting which antipsychotic is to be prescribed in an individual schizophrenia patient represents an important clinical decision that need to take into account efficacy and side effects.
Psychiatry , — MD has received research grant support, travel support, speaker fees, or Dickinson, D. Psychiatry 64 5 , — RSK has received grants, honoraria for education programmes, or served Fleischhacker, W. Longitudinal studies of cognition Marder, S. Guy, W. In: RushJr. Pincus, H. Delineating psychomotor slowing from reduced Handbook of Psychiatric Measures. American Psychiatric Association, processing speed in schizophrenia.
Neuropsychiatry 13 6 , — Washington, pp. Morrens, M. Psychomotor slowing in Harris, A. Sensorimotor and cognitive slowing in schizophrenia as measured by the Heydebrand, G. Norman, R. Duration of untreated psychosis Schizophr. Psychiatry , Ho, B. Psychiatry 1 , attention: normal performance in patients with early-onset schizophrenia.
Hoff, A. Lack of association between duration of untreated illness and Arolt, V. Neuropsychologia 46 1 , — Psychiatry 11 , — Pencer, A. Substance use and cognition in early Kahn, R.
Gheorghe, M. Relationship between Dollfus, S. Effective- a critical review and meta-analysis. Psychiatry 10 , — Lancet , Characterizing and dating the onset of symptoms in psychotic — Kay, S.
The positive and negative syndrome Res. Reitan, R.
The Halstead—Reitan neuropsychological test Keefe, R. Should cognitive impairment be included in the diagnostic battery: theory and clinical interpretation, second ed. Neuropsychology criteria for schizophrenia? World Psychiatry 7 1 , 22— Press, Tucson.
Klingberg, S. Disorganization and Rey, A. L'Examen clinique en psychologie. Presses Universitaires de cognitive impairment in schizophrenia: independent symptom dimen- France, Paris. Psychiatry Clin. Rund, B. Heterogeneity of schizophrenia: a study of individual neuropsychological 39 2 , — Serper, M. Learning and memory impairment in cocaine-dependent and Fearon, P.
Psychiatry Res. Duration of untreated psychosis and neuropsychological function Sevy, S. Leeson, V. The relationship between IQ, memory, executive Hergueta, T. The Mini-International function, and processing speed in recent-onset psychosis: 1-year stability Neuropsychiatric Interview M.
Psychiatry 59 Suppl 20 , 22— Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry References ; 60 6 : — Drug Saf ; S.
Service availability and utilization and treatment gap for 25 15 ; — Abnormal glucose metabolism in countries. Bulletin of the World Health Organization ; 90 1 : patients treated with antipsychotics.
Diabetes and Metabolism B. Journal of Clinical Psychiatry people with serious mental illness and other major disorders from ; 63 4 : — PLoS One Pharmacological treatments for first-episode schizophrenia. Tanskanen A, Haukka J. Kurzthaler I, Fleischhacker WW.
The clinical implications of with schizophrenia: a population-based cohort study FIN11 study. Journal of Clinical Psychiatry ; Lancet ; : — 62 Suppl 7 : 32— Mortality in schizophrenia: Perkins DO. Predictors of noncompliance in patients with a measurable clinical endpoint.
J Psychopharmacol ; 24 4 schizophrenia. Journal of Clinical Psychiatry ; 63 12 : — Suppl : 17— Parks J. Morbidity and Mortality Antipsychotic-induced weight gain: in People with Serious Mental Illness.
How the world could better fight 6. Twenty-five year obesity. Accessed November , mortality of a community cohort with schizophrenia.
Antipsychotic drugs versus placebo for relapse Aursnes I. A review and Bayesian meta-analysis of clinical efficacy prevention in schizophrenia: a systematic review and meta-analysis. J Clin Psychopharmacol ; 31 6 : 8. Schizophr Res Almost ; 1 : PLoS One 9. Mortality and its determinants in people Citrome L.
A review of the pharmacology, efficacy and V. Weight gain, an evidence-based medicine approach. CNS Drugs ; 27 11 : schizophrenia and antispychotics: new findings from animal model — Schizophr Res Treatment ; vol.
Prescribing of antipsychotics in UK primary care: a cohort study. Genetics of antipsychotic treatment BMJ Open ; 4 12 : e emergent weight gain in schizophrenia.
Pharmacogenomics ; Genetic determinants of variable metabolism have little impact on Genet Metabolic and cardiovascular adverse effects associated with Med ; 10 10 : — Nat Rev Endocrinol ; 8 2 : — Complex HTR2C change from 3-year observational data: findings from the linkage disequilibrium and promoter associations with body mass worldwide schizophrenia outpatient health outcomes database.
Hum Genet ; 6 : — J Clin Psychiatry ; 73 6 : — Comparison of metabolic study.
J Clin Psychiatry ; 69 9 : — Association study of energy homeostasis Copyright of Acta Endocrinologica is the property of Acta Endocrinologica Foundation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission.
However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy.
Users should refer to the original published version of the material for the full abstract. Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.